Related references
Note: Only part of the references are listed.The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform
Aaron S. Kesselheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
Jason C. Gallagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2014)
Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection
R.U. Varier et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
High-Cost Generic Drugs - Implications for Patients and Policymakers
Jonathan D. Alpern et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lack of Health Insurance Coverage for Oral Vancomycin: It's Time to Tackle the Elephant in the Room
Alex Studemeister
CLINICAL INFECTIOUS DISEASES (2011)
Share Paper
